Delivery Order SPE2DB22D2206-SPE2DB25FKD43
- Not listed
- The Defense Logistics Agency awarded a $15,953.54 delivery order to AmerisourceBergen Drug Corp for FOTIVDA 1.34 mg capsule supply (21-count units) on August 4, 2025, with an ultimate completion date of August 25, 2025. This firm fixed-price contract is not set-aside and represents a competitive award under the company's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The delivery will be performed at...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of FOTIVDA 0.89 mg capsules (21 count), with a ceiling value of $32,270.40 and a firm fixed price structure. This non-set-aside delivery order is scheduled for completion by September 12, 2025, and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $15,953.54 delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for FOTIVDA 1.34 mg capsules (21-count). This contract, which is non-set-aside and competitively awarded, is structured as a firm fixed price delivery order with a completion date of August 21, 2025. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order represents a child contract under...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of FOTIVDA 0.89 MG CAPSULE 21S. The contract has a firm fixed price of $16,135.20 and a period of performance extending to July 3, 2025. It is not a set-aside contract, indicating open competition. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical valued at $999,999,999.00, which serves as a...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $31,907.08 to AmerisourceBergen Drug Corp for FOTIVDA (tivozanib) 1.34 mg capsules (21-count units) on August 21, 2025, with an ultimate completion date of September 12, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and is being performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award represents a child order under AmerisourceBergen's larger...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of FOTIVDA 1.34 MG CAPSULE 21S, a pharmaceutical product, with a ceiling value of $15,953.54 and a completion date of July 2, 2025. The contract is a firm fixed-price delivery order, without any set-aside designation, indicating open competition. Amerisourcebergen Drug Corp is the...
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a for-profit organization, to provide FOTIVDA 1.34 MG CAPSULE 21S, a pharmaceutical product, with a potential value of $30,841.18. The contract has a completion date of February 16, 2024 and was awarded on January 26, 2024. Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, is the prime contractor and is not operating under any set-aside designation. This...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of the for-profit Amerisourcebergen Corporation. The contract, valued at $15,420.59, is for the delivery of FOTIVDA 1.34 MG CAPSULE 21S pharmaceutical products to Conshohocken, Pennsylvania. This delivery order is issued under a larger, single-award indefinite delivery contract (IDC) held by Amerisourcebergen Drug Corp with DLA, with a potential value up to...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, through its Corporate Office division, to provide FOTIVDA 0.89 MG CAPSULE 21S, a specialty pharmaceutical product, with a ceiling value of $32,652.72 and a performance period through April 25, 2024. The award is a firm fixed price contract and does not have a set-aside designation. AmerisourceBergen Drug Corp is the prime contractor and serves as a key supplier of pharmaceuticals and medical...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of FOTIVDA 1.34 MG CAPSULE 21S. The contract has a firm fixed price of $31,907.08 and a completion date of June 3, 2025. This delivery order is part of a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, valued at $999,999,999.00, which provides a comprehensive global pharmaceutical...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FKD43Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for FOTIVDA 0.89 mg capsules (21-count) on September 28, 2025, with a contract ceiling value of $64,177.48 and an ultimate completion date of October 20, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and represents a pharmaceutical procurement supporting military and federal healthcare needs. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is executed under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor, AmerisourceBergen serves as a prime vendor for the Defense Health Agency and other federal healthcare systems, supplying an extensive portfolio of brand-name and generic medications, vaccines, and specialized medical supplies across multiple therapeutic domains. The company's track record of competitively awarded federal contracts demonstrates its capability to fulfill critical pharmaceutical procurement requirements for military and veteran healthcare programs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $64.2k | 9/28/25 |